臨床および実験皮膚科学研究ジャーナル
オープンアクセス

概要

Hormone Replacement Therapy and Cutaneous Manifestations of Systemic Lupus Erythematosus

Fatemeh Zahra Seyed-Kolbadi1*, Kosar Gorgin1, Mohamad Hossein Zarei1, Mina Keshavarz1, Marzieh Bonyadi1, Alireza Malektojari1, Reza Farrokhseresht2

Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. Presentation of SLE can range from mild skin symptoms to severe organ damage. Skin manifestations, as one of the most diagnostic signs of SLE, containing a broad range of skin rashes and vascular involvements which can highly be affected by disease flares and medications. Hormone Replacement Therapy (HRT) as a common medication used for infertility treatment and relief of menopausal and postmenopausal symptom can also modify SLE complications. Studies show that the use of oral contraceptives in SLE patients is not recommended but for SLE patients in childbearing age planned pregnancy or the use of assess reproductive technology could be recommended. Receiving HRT can improve menopausal/ postmenopausal symptoms and bone mineral density along with increasing thrombotic events and can generally be recommended. Due to the mild increase in SLE flare and its cutaneous manifestations by HRT, after considering the patient specific cost-effectiveness of intended intervention, SLE patients can receive HRT safely. However specific inferences in this area could be done when more related studies are available.